Figure 5.

Glutriptolide-2 Improves Survival in an In-Vivo Prostate Cancer Model

(A) G-2 and G-1 have similar maximum tolerable dose (MTD) in a metastatic prostate cancer model. After confirmation of tumor growth in NOD/SCID/IL2r^null mice by bioluminescence imaging, daily administration of 1 mg/kg G-1 or G-2 for 30 days was tolerated by animals and able to suppress tumor growth throughout the treatment. Anti-tumor effect by G-1 or G-2 persists 2 weeks posttreatment.

(B) Kaplan-Meier curves showing survival time (days after initiation of treatments [n = 5]) for controls, G-1, or G-2 treatments. Median survival times (days) are as follows: nontreated = 27, DMSO = 29, G-1 (1mg/kg) = 76, G-2 (0.25mg/kg) = 46, G-2 (0.5mg/kg) = 76, G-2 (1mg/kg) = 84.